Introduction
============

Deletions affecting the proximal long arm of chromosome 3 are rarely reported in the literature. Hitherto, 14 patients have been described with deletions of various sizes and different breakpoints within the 3q11q23 region. The deletions were investigated in nine of the patients by standard karyotyping[@b1; @b2; @b3; @b4; @b5; @b6; @b7; @b8] and only five cases have been investigated by molecular methods.[@b9; @b10; @b11; @b12; @b13; @b14] The 14 patients had a range of different phenotypes including cranial and facial dysmorphisms, developmental retardation, and genital and peripheral musculoskeletal abnormalities. However, determining a proper genotype---phenotype correlation has been hampered by the few cases with molecularly defined deletions as well as by the limited number of patients described.

The advent of high resolution microarray techniques has greatly facilitated the investigation of chromosomal disorders, enabling the identification of disease-causative genes for known syndromes---for example, CHARGE syndrome (OMIM 214800) and 9q subtelomeric deletion syndrome (OMIM 610253) as reviewed in Vissers *et al*.[@b15] In addition, a number of novel microdeletion and microduplications syndromes have been delineated, starting with the first described 17q21.31 microdeletion syndrome in 2006 (reviewed in Vissers *et al* [@b15]). Moving from a cytogenetic approach to an ever more sensitive molecular karyotyping has reversed the strategy behind the identification of novel syndromes---that is, patients having similar/overlapping genetic rearrangements are identified before the clinical characteristics of a syndrome are defined. Furthermore, the collection of clinical and genetic information in databases such as DECIPHER,[@b16] ISCA,[@b17] and ECARUCA[@b18] has been crucial for the comparison between patients with rare aberrations.

Using a reverse genetics approach and a joint collaborative effort through DECIPHER, we describe 14 novel patients carrying microscopic or submicroscopic deletions in the region 3q12.3q21.3. In addition, a molecular investigation is presented of a previously reported 3q-deletion patient.[@b5] This study also presents a review of the 13 previously reported patients. A newly recognised 3q13.31 microdeletion syndrome is identified, characterised by developmental delay, postnatal growth above the mean, characteristic facial features, and abnormal male genitalia. The phenotype is associated with a 0.6 Mb critical region harbouring two strong candidate genes for the developmental delay, the *DRD3* and *ZBTB20* genes.

Patients and methods
====================

Patients
--------

In the present study, 15 patients were included with deletions in the proximal long arm of chromosome 3. One patient, case 2, was previously described clinically and cytogenetically by Ogilvie *et al* 1998,[@b5] while the remaining 14 patients are novel. Clinical information was systematically collected from clinicians, using supplementary table 1.

The WHO Child Growth Standards were used to standardise birth height, weight, and occipitofrontal circumference (OFC) for all novel patients and for the previously reported patients where growth parameters were given.[@b19] WHO standards are available up to 19 years of age for height and up to 10 years of age for weight. To assess OFC after birth the German head circumference references were used, which extend up to 18 years of age.[@b20]

The clinical investigations and genetic analyses were performed according to the guidelines in the Declaration of Helsinki and were approved by the ethics committee of Uppsala University. Informed consent was obtained from all family members and specific permission to publish photographs was obtained.

Methods
-------

Molecular investigation of the 15 patients was conducted using different array platforms ([table 1](#tbl1){ref-type="table"} and supplementary material) according to the manufacturer\'s instructions. The identified deletions were confirmed using karyotyping or fluorescence in situ hybridisation (FISH) (supplementary material) and parental testing was performed when parental DNA was available (13/15 cases). Deletions in cases 1 and 2 were microscopically visible and had initially been investigated using GTG banding.[@b5] The positions of the deletions were mapped to the human NCBI/hg18 assembly of the UCSC genome browser (<http://genome.ucsc.edu/>).

###### 

Molecular characterisation of 3q12q21 deletions in present and previously published patients

  Case                                                       Chromosomal band                       Start (hg18)   End (hg18)    Size (Mb)   No of RefSeq genes   Inheritance        Method
  ---------------------------------------------------------- -------------------------------------- -------------- ------------- ----------- -------------------- ------------------ -----------------------------------------------------
  Case1                                                      q12.3--q13.31                          103332789      118628997     15.30       64                   De novo            Affymetrix GeneChip 250K Nsp/G-banding
  Case2                                                      q12.3--q13.33                          103481815      122521004     19.04       89                   De novo            Affymetrix GeneChip 250K Nsp/G-banding
  Case3                                                      q13.11--q13.31                         105180963      118326520     13.15       63                   De novo            1 Mb clone array/FISH
  Case4                                                      q13.11--q21.3                          105782523      128177975     22.40       144                  De novo            Agilent array CGH 400K/Q-PCR
  Case5                                                      q13.11--q13.33                         105911706      120983616     15.07       78                   De novo            Agilent array CGH 44K/Q-PCR
  Case6                                                      q13.13--q13.33                         110116098      122633570     12.52       73                   De novo            Agilent array CGH 44K/FISH RP11-233L3
  Case7                                                      q13.13--q13.31 (inv(3)(q13.1;q26.3))   111722434      117006477     5.28        39                   De novo            Agilent array CGH 44K/FISH RP11-105H23
  Case8                                                      q13.2--q13.32                          112976429      120183473     7.2         38                   Not tested         Affymetrix GeneChip 250K Nsp
  Case9                                                      q13.2--q13.31                          113680819      116466363     2.79        24                   De novo            Agilent array CGH 44K/FISH RP11-572C15
  Case10                                                     q13.2--q13.31                          113764648      116429950     2.67        22                   De novo            BlueGnome CytochipV2/FISH RP11-572C15
  Case11                                                     q13.2--q13.31                          113764648      116429950     2.67        22                   De novo            BlueGnome CytochipV2/FISH RP11-572C15 and RP11-58D2
  Case12                                                     q13.2--q13.31                          114490215      116264578     1.77        15                   De novo            Affymetrix genome-wide human SNP Array6.0
  Case13                                                     q13.31--q13.31                         115335356      115916848     0.58        5                    De novo            Affymetrix GeneChip 250K Nsp
  Case14                                                     q13.31--q13.31                         116922662      118098190     1.18        3                    Absent in mother   Agilent Array CGH 44K/FISH RP11-91D11
  Case15                                                     q13.32--q21.2                          119261437      126585699     7.32        63                   De novo            SpectralChip CC4-V0.3/FISH RP11-169N13
  Kosaki[@b10][\*](#table-fn1){ref-type="table-fn"}          q12.2--q13.2                           101480701      114803431     13.32       70                   De novo            Spectral Genomics human BAC array 2500/G-banding
  Malan[@b11][\*](#table-fn1){ref-type="table-fn"}           q13.11--q13.33                         104531502      122804242     18.27       91                   De novo            Agilent 244K/FISH
  Simovich[@b14][\*](#table-fn1){ref-type="table-fn"}        q13.11--q13.12                         105652857      108151059     2.50        2                    De novo            Illumina HumanHap550 Beadchip/FISH RP11-91B3
  Shimojima[@b13][\*](#table-fn1){ref-type="table-fn"}       q13.2--q13.31                          114321633      116406833     1.9         16                   De novo            Agilent array CGH 105A/FISH
  Hou[@b9]/Sato[@b12][\*](#table-fn1){ref-type="table-fn"}   q11.2--q13.31 t(3;12)(q13.2;p11.2)     97002372       116490074     19.49       107                  De novo            BAC array CGH/FISH
  Lawson-Yuen[@b4][\*](#table-fn1){ref-type="table-fn"}      q13.1--q13.3                           *104400000*    *123400000*                                    De novo            Chromosome analysis
  Okada[@b6][\*](#table-fn1){ref-type="table-fn"}            q12--q21                               *99800000*     *131500000*                                    De novo            G-banding, Q
  Fujita[@b1][\*](#table-fn1){ref-type="table-fn"}           q12--q23                               *99800000*     *144400000*                                    De novo            G-banding
  Genuard[@b2][\*](#table-fn1){ref-type="table-fn"}          q13.12--q21.3                          *107800000*    *131500000*                                    De novo            G-banding
  Jenkins[@b3][\*](#table-fn1){ref-type="table-fn"}          q11--q21                               *91700000*     *131500000*                                    De novo            G-banding
  Ogilvie[@b5][\*](#table-fn1){ref-type="table-fn"}          q12--q21                               *99800000*     *131500000*                                    De novo            G-banding
  McMorrow[@b7][\*](#table-fn1){ref-type="table-fn"}         q12--q21                               *99800000*     *131500000*                                    De novo            G-banding, Q and C
  Arai[@b8][\*](#table-fn1){ref-type="table-fn"}             q12--q22                               *99800000*     *131500000*                                    De novo            

Previously published cases with the reference indicated; Start- and endpoints in italic indicates maximum estimated start and end.

BAC, bacterial artificial chromosome; CGH, comparative genomic hybridisation; FISH, fluorescence in situ hybridisation; SNP, single nucleotide polymorphism.

Results and discussions
=======================

Molecular details
-----------------

We present the clinical and molecular features of 15 novel patients harbouring deletions of the proximal long arm of chromosome 3. One of the patients was reported cytogenetically in the late 1990s[@b5] (case 2). The present study also provides a review of 13 previously reported patients.[@b1; @b2; @b3; @b4; @b5; @b6; @b7; @b8; @b9; @b10; @b11; @b12; @b13; @b14] The deletions are mapped within 3q12.3q21.3 and they range in size from the smallest of 580 kb (case 13) to the largest of 22.4 Mb (case 4) ([figure 1](#fig1){ref-type="fig"} and [table 1](#tbl1){ref-type="table"}). Most of the deletions have different breakpoints, although the breakpoints in cases 9, 10, 11, and 12 are in close proximity ([figure 1](#fig1){ref-type="fig"}); the breakpoints of these patients are approximately located at 113.5--116.5 Mb. In all but one case, the deletion was the sole identified aberration. In case 7, an inversion was identified (inv(3)(q13.1q26.3)) and the deletion was located at the 3q13.1 inversion breakpoint. The deletions showed a de novo occurrence in 13 cases. Parental DNA was not available for testing in case 8, whose 7.2 Mb deletion is likely to have arisen de novo because of the size and gene content of this deleted region. Carrier testing in the parents of case 14 was only possible in the mother\'s DNA, which revealed a normal chromosome 3.

![A physical map of the chromosomal region 3q11.2 to 3q23, illustrating the deletions. The deletions identified in novel patients are shown in black, previously reported deletions that have been molecularly characterised are shown in dark grey, and previously reported deletions that have been cytogenetically characterised are shown in light grey. RefSeq genes are indicated in blue. The grey solid box illustrates the shortest region of overlapping deleted region, and a zoomed view shows the five RefSeq genes within this region (bottom panel).](jmedgenet-2011-100534fig1){#fig1}

The shortest region of overlapping deletion (SRO) is delineated by case 13, with estimated breakpoints at genomic positions 115.33---115.39 Mb ([figure 1](#fig1){ref-type="fig"}). This 580 kb segment includes five RefSeq genes: *DRD3*, *ZNF80*, *TIGIT*, *MIR568*, and *ZBTB20*. The SRO is shared by 13 of the novel patients, and by 11 of the previously reported patients---that is, 24 cases in total. The SRO is within the previously reported smallest deletion which was 1.9 Mb in size.[@b13] However, the 2.5 Mb deletion identified in the case presented by Simovich *et al* is located at 3q13.11q12 and hence does not overlap with the region defined in the present study.[@b14] Four cases do not have an overlapping deletion with the SRO, namely case 14, case 15 (both from this study), Kosaki *et al*,[@b10; @b14] and Simovich *et al*.[@b10; @b14]

Clinical data
-------------

In total, clinical data from 28 patients, both novel and previously published cases, were collected and are summarised in supplementary table 1. Photographs of some of the novel patients (cases 1, 2, 4, 5, 6, 7, 9, 12 and 15) are shown in [figure 2](#fig2){ref-type="fig"}. The clinical findings in the 24 patients sharing the SRO (115.33---115.39 Mb) are summarised separately, and the frequency of these features was calculated (supplementary table 1, frequency column). These features include normal pregnancy and delivery at term with a few exceptions.[@b1] [@b4] [@b5] [@b11] [@b14] Developmental delay is the most prevalent feature, present in 19/21 cases. Two cases did not suffer from developmental delay (case 7) or had not been examined at the time of the report due to the patient\'s young age (case 4). However, case 7 displayed attention deficit disorder. There are eight patients presenting with autism or attention deficits and one with epilepsy, including case 7. In 15 of 17 cases speech was delayed, and in three of these 15 patients the speech was minimal/no meaningful words were used/communication by hands by the age of 4.5, 8, and 18 years. Muscular hypotonia was found in 12/15 patients. Interestingly, muscular hypotonia was suggested by Shimojima *et al* to be the only common finding along with developmental delay in patients with 3q13 deletions[@b13]. The brain and central nervous system were also affected: five patients had agenesis of the corpus callosum, three patients had ventriculomegaly, and one had alobar holoprosencephaly. In total, seven patients displayed skull malformations: two with dolichocephaly, two with plagiocephaly, and three with brachycephaly. Furthermore, 10/13 patients presented with broad and prominent forehead.

![Photographs of cases 1, 2, 4, 5, 6, 7, 9, 10, 12, and 15. Physical characteristics of note are short philtrum, protruding lips with full lower lips and tented upper lips, hypertelorism, and antimongoloid slanted eyes present in several cases.](jmedgenet-2011-100534fig2){#fig2}

Distinct recognisable facial features, including short philtrum, protruding lips with full lower lips and tented upper lips, antimongoloid slanted eyes, and hypertelorism, were apparent in several cases ([figure 2](#fig2){ref-type="fig"}). In total, the facial features in the 24 patients were short philtrum in 6/6, epicanthal folds in 8/14, hypertelorism in 7/17, antimongoloid slant in 7/13, a high arched palate in 7/10, and ptosis in 4/11. Ocular malformation included strabismus in 6/14 and myopia in 4/8. The ears were large in 5/15 and were low set in 4/15.

There was a high prevalence of abnormal external male genitalia, affecting 11/15 males. The abnormalities included micropenis (4/15), microorchidism (2/15), cryptorchidism (7/15), and shawl scrotum (2/15). All female patients had normal genitalia.

Skeletal malformations were a frequent finding, present in as many as 16/24 patients. The skeletal malformations included scoliosis, lordosis, thoracic kyphosis, joint contractures, and peripheral malformations affecting the hands and feet. Of note were the proximally set thumbs present in three novel cases (cases 2, 4, and 9).

Growth parameters were assessed in the 24 patients sharing the SRO and 4/11 (cases 4, 5, 9, and 10) had a birth OFC \>85th centile (7/11 had a birth OFC \>50th centile). OFC was also available at a later age and 9/20 had an OFC \>85th centile (11/20 had an OFC \>50th centile). Case 6 is noteworthy, having a birth OFC between 15--50th centile and an OFC between 85--97th centile at the age of 4 years and 10 months. The weight and length parameters were also reviewed and these were normal at birth, 5/16 had a weight \>50th centile, 5/12 had a length \>50th centile, and none of the patients displayed a weight or length \>85th centile. At the time of report, 10/19 had a weight \>50th centile and 9/19 had a weight \>85th centile. Regarding height at the time of report, 13/21 were \>50th centile and 10/21 were \>85th centile. Hence, a postnatal growth pattern above the mean was observed among these patients. A larger region, encompassing 18.2 Mb in q13.11q13.33, has previously been identified in a screening of patients with syndromic overgrowth, and the present report delineates the overgrowth candidate region to 3q13.31. In DECIPHER, most of the listed microdeletion/microduplication syndromes are associated with short stature, while there is one that is characterised by tall stature---the 15q26 overgrowth syndrome. Regarding OFC, there is one listed microdeletion/microduplication syndrome in DECIPHER with macrocephaly, the 1q21.1 microduplication syndrome, in comparison with microcephaly that is present in 13 of the DECIPHER listed syndromes. Known overgrowth syndromes are Sotos syndrome, Beckwith---Wiedeman syndrome, Simpson---Golabi---Behmel syndrome, Klinefelter syndrome, homocystinuria and Marfan syndrome.[@b21] The molecular knowledge about overgrowth syndromes is thus fairly limited and, in this context, the present report provides novel clues to finding genes involved in growth.

Candidate genes
---------------

The proximal long arm of chromosome 3 is a gene dense region ([figure 1](#fig1){ref-type="fig"}) with 145 genes within the estimated boundaries (chr3:103.32--128.18 Mb) of the 15 novel patients. Hence, a number of genes could potentially contribute to the phenotypic features of these patients. Regarding the five RefSeq genes present in the SRO, two (*DRD3* and *ZBTB20)* are particularly interesting with respect to developmental delay, the neuropsychiatric features, and the structural brain, central nervous system, and skull malformations. *DRD3* encodes D3 subtype of the dopamine receptors, which is localised to the limbic areas of the brain, and is involved in locomotion, cognition, emotion, and affection as well as neuroendocrine secretion.[@b22] Targeted mutation of *DRD3* is associated with hyperactivity in mice, and recent association studies in patients with neuropsychiatric disorders have explored the contribution of *DRD3* variants to their phenotype.[@b23; @b24; @b25] The *ZBTB20* gene belongs to the BTB/POZ zinc finger family and is expressed in the developing hippocampal neurons.[@b26] Downregulation of ZBTB20 disturbs the normal maturation of a certain type of neurons in the hippocampus, and changes in the cortical cytoarchitecture---for example, lack of the posterior part of the corpus callosum---were observed in transgenic mice models.[@b27] [@b28] One additional interesting aspect of ZBTB20, with respect to the observed postnatal overgrowth in the patients, is the fact that it regulates genes involved in growth and metabolism.[@b29]

In addition to the SRO and the genes therein, the present study provides clues about other 3q genomic regions harbouring important genes with respect to normal development. First, the deletion in case 14, telomeric of the SRO, contains *LSAMP* and *GAP43*, two strong candidate genes for developmental delay. *LSAMP* encodes the limbic system associated membrane protein, and studies in both human and mice models have demonstrated the involvement of LSAMP in neuropsychiatric features and behaviour.[@b30] [@b31] GAP43 is involved in neurite outgrowth, neurotransmission, and synaptic plasticity among other functions and *GAP43* was also recently identified as a candidate gene for autism and autistic-like manifestations in human and mice.[@b32; @b33; @b34] In addition, *Gap43* +/− mice display decreased corpus callosum and hippocampal commissure volume.[@b34] Secondly, the present study supports the previous suggestion that 3q11 could harbour a locus for agenesis of the corpus callosum (ACC).[@b2] [@b35] Five previously published 3q deletion patients exist who displayed ACC.[@b2] [@b4] [@b5] [@b7] [@b35] Here we present one novel patient (case 6) with ACC, having a deletion that can help with further refining of the ACC critical region. As discussed above, strong candidate genes involved in ACC are *ZBTB20* and *GAP43*.

Further support underlining the importance of *DRD3*, *ZBTB20*, *LSAMP*, and *GAP43* in contributing to the phenotype in patients with 3q13 deletions is their haploinsufficiency score, as defined by the study by Huang *et al*.[@b36] There are 49 genes of the total of 145 genes in 3q12-q21 that have a haploinsufficiency score of \<50%, and these four candidate genes are among those 49 (supplementary table 2).

Conclusion
==========

The present study describes a newly recognised 3q13.31 microdeletion syndrome based on 24 novel and previously reported patients and suggests candidate genes responsible for the developmental delay. In addition, the age of the patients in this report, ranging from infant to 20 years, provides prognostic information for patients with this microdeletion syndrome.
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